Singhal Vibha, Karzar Nazanin Hazhir, Bose Amita, Buckless Colleen, Ackerman Kathryn E, Bredella Miriam A, Klibanski Anne, Misra Madhusmita
Neuroendocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States; Division of Pediatric Endocrinology, Mass General Hospital for Children and Harvard Medical School, Boston, MA, United States; MGH Weight Center, Massachusetts General Hospital, Boston, MA, United States.
Neuroendocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States.
Bone. 2021 Apr;145:115841. doi: 10.1016/j.bone.2021.115841. Epub 2021 Jan 6.
Low energy availability causes disruption of hypothalamic gonadotropin-releasing hormone secretion leading to functional hypothalamic amenorrhea (FHA) and hypoestrogenism, which in turn contributes to decreased bone mineral density (BMD) and increased bone marrow adipose tissue (MAT). Transdermal estradiol administration in physiologic doses increases BMD in adolescents and adults with FHA. However, the impact of estrogen replacement on MAT in relation to changes in BMD has not been studied in adolescents and young adults. We hypothesized that physiologic estrogen replacement would lead to decreases in MAT, associated with increases in BMD.
We studied 15 adolescent and young adult females with FHA (14-25 years). All participants received a17β- estradiol transdermal patch at a dose of 0.1 mg/day (applied twice weekly) for 12 months. Participants also received cyclic progestin for 10-12 days each month. We quantified MAT (lipid/water ratio) of the fourth lumbar (L4) vertebral body and femoral diaphysis by single proton (1H)-magnetic resonance spectroscopy, and compartmental volumetric BMD of the distal radius and tibia using high-resolution peripheral quantitative computed tomography.
Transdermal estradiol therapy over 12 months resulted in a decrease in MAT at the lumbar (L4) vertebra from 0.92 ± 0.55 at baseline to 0.63 ± 0.29 at 12-months (p = 0.008), and an increase in radial and tibial cortical vBMD (p = 0.006, p = 0.0003). Changes in L4 MAT trended to be inversely associated with changes in radial cortical vBMD (rho = -0.47, p = 0.08).
We show that in adolescent and young adult girls with FHA, MAT decreases following transdermal estrogen therapy and these changes are associated with increased cortical vBMD.
低能量可用性会导致下丘脑促性腺激素释放激素分泌紊乱,进而引发功能性下丘脑闭经(FHA)和雌激素缺乏,这反过来又会导致骨密度(BMD)降低和骨髓脂肪组织(MAT)增加。经皮给予生理剂量的雌二醇可增加患有FHA的青少年和成年人的骨密度。然而,在青少年和年轻成年人中,雌激素替代对MAT与骨密度变化关系的影响尚未得到研究。我们假设生理雌激素替代会导致MAT减少,并与骨密度增加相关。
我们研究了15名患有FHA的青少年和年轻成年女性(14 - 25岁)。所有参与者接受剂量为0.1毫克/天的17β - 雌二醇经皮贴片(每周两次),持续12个月。参与者每月还接受10 - 12天的周期性孕激素治疗。我们通过单质子(1H)磁共振波谱法对第四腰椎(L4)椎体和股骨干的MAT(脂质/水比率)进行定量,并使用高分辨率外周定量计算机断层扫描对桡骨远端和胫骨的分区体积骨密度进行测量。
12个月的经皮雌二醇治疗导致腰椎(L4)椎体的MAT从基线时的0.92±0.55降至12个月时的0.63±0.29(p = 0.008),桡骨和胫骨皮质体积骨密度增加(p = 0.006,p = 0.0003)。L4椎体MAT的变化趋势与桡骨皮质体积骨密度的变化呈负相关(rho = -0.47,p = 0.08)。
我们表明,在患有FHA的青少年和年轻成年女性中,经皮雌激素治疗后MAT会减少,且这些变化与皮质体积骨密度增加相关。